Niels Laursen
Director of Finance/CFO at BIOSERGEN AB
Network origin in Niels Laursen first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Pharmaceuticals: Major | 16 | |
10
| Public Company | Biotechnology | 10 |
Bjørn Svendsen København A/S
3
| Subsidiary | 3 | |
Medical Prognosis Institute A/S
 Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark.
1
| Extinct | Biotechnology | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Niels Laursen via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chairman Chairman | |
| MORPHOSYS AG | Biotechnology | Chief Tech/Sci/R&D Officer | |
Astion Pharma A/S
 Astion Pharma A/S Pharmaceuticals: MajorHealth Technology Astion Pharma A/S develops and manufactures pharmaceutical products. It focuses on developing anti-inflammatory drugs for dermatological and immunological diseases. The company was founded by Morten S. Weidner in 1992 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| Karolinska Institutet | College/University | Doctorate Degree Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| University of Kiel | College/University | Doctorate Degree | |
| University of Cincinnati (Ohio) | College/University | Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| University of Aarhus | College/University | Doctorate Degree Corporate Officer/Principal | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree | |
Rosetta Capital Ltd.
 Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
| Heinrich-Heine-Universität Düsseldorf | College/University | Doctorate Degree | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder Director/Board Member | |
EyeSense GmbH
 EyeSense GmbH Electronic Equipment/InstrumentsElectronic Technology EyeSense GmbH develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. It is developing two different diagnostic systems: An ophthalmic sensor which-once inserted on the eye-can be read out optically as frequently as wanted, without any pain and a continuous sensor, to be worn on the abdomen or upper arm. The firm with its innovative sensor technology able to offer two products that addresses different needs in blood glucose monitoring which are Continuous Glucose Sensor and Eye Sensor. The company was founded in 2006 and is headquartered in Großostheim, Germany. | Electronic Equipment/Instruments | Director/Board Member | |
| FORWARD PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Sti Technologies Ltd.
 Sti Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services STI Technologies Ltd. provides marketing solutions to the health care industry. The firm's SmartTechnology platform allows stakeholders-manufacturers, pharmacies, prescribers, and payers to optimize their patient relationships. It offers solutions for pre-launch planning, brand adoption, market uptake, revenue optimization, retention and adherence, and loss of exclusivity. The company was founded by William B. Adams and Gregory Patey in 2001 and is headquartered in Halifax, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Chairman Chief Executive Officer | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Chairman Chief Executive Officer | |
| Merck Generics | Corporate Officer/Principal | ||
| WNTRESEARCH AB | Pharmaceuticals: Other | Chairman Corporate Officer/Principal | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman Chairman | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chairman Director/Board Member | |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| CIRCIO HOLDING ASA | Biotechnology | Director/Board Member Chief Executive Officer | |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member | |
Allarity Therapeutics Europe ApS
 Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer | |
| Cytochrome Ltd. | Director/Board Member | ||
Liplasome Pharma ApS
 Liplasome Pharma ApS Pharmaceuticals: MajorHealth Technology Liplasome Pharma ApS operates as a biotech company focusing on oncology. It develops drug delivery technologies for anticancer market. The firm's drug delivery platform consists of a lipid based drug delivery system for the intravenous transportation of anticancer drugs and prodrugs. The company was founded in 2002 and is headquartered in Hoersholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| Vistagen Pte Ltd. | Miscellaneous | Director/Board Member | |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Pharmaceuticals: Major | Founder Director of Finance/CFO Chairman Chief Operating Officer Corporate Officer/Principal | |
| CHOSA ONCOLOGY AB | Miscellaneous Commercial Services | Chief Executive Officer Chief Operating Officer | |
| Buhl Krone Holding ApS | Corporate Officer/Principal Chief Executive Officer |
Statistics
International
| Denmark | 20 |
| Sweden | 14 |
| United States | 6 |
| Germany | 5 |
| Norway | 4 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Finance | 4 |
| Electronic Technology | 2 |
Operational
| Director/Board Member | 201 |
| Chairman | 67 |
| Corporate Officer/Principal | 59 |
| Chief Executive Officer | 51 |
| Independent Dir/Board Member | 39 |
Most connected contacts
- Stock Market
- Insiders
- Niels Laursen
- Company connections
